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Inborn errors of metabolism (IEMs) are hereditary metabolic defects, which are encountered in
almost all major metabolic pathways occurring in man. Many IEMs are screened for in neonates
through metabolomic analysis of dried blood spot samples. To enable the mapping of these
metabolomic data onto the published human metabolic reconstruction, we added missing
reactions and pathways involved in acylcarnitine (AC) and fatty acid oxidation (FAO)
metabolism. Using literary data, we reconstructed an AC/FAO module consisting of 352 reactions
and 139 metabolites. When this module was combined with the human metabolic reconstruction,
the synthesis of 39 acylcarnitines and 22 amino acids, which are routinely measured, was captured
and 235 distinct IEMs could be mapped. We collected phenotypic and clinical features for each
IEM enabling comprehensive classiﬁcation. We found that carbohydrate, amino acid, and lipid
metabolism were most aﬀected by the IEMs, while the brain was the most commonly aﬀected
organ. Furthermore, we analyzed the IEMs in the context of metabolic network topology to gain
insight into common features between metabolically connected IEMs. While many known
examples were identiﬁed, we discovered some surprising IEM pairs that shared reactions as well
as clinical features but not necessarily causal genes. Moreover, we could also re-conﬁrm that
acetyl-CoA acts as a central metabolite. This network based analysis leads to further insight of
hot spots in human metabolism with respect to IEMs. The presented comprehensive knowledge
base of IEMs will provide a valuable tool in studying metabolic changes involved in inherited
metabolic diseases.
Introduction
Inborn errors of metabolism (IEMs) are individually rare but
collectively numerous, aﬀecting the metabolism of many human
organs. These metabolic defects are congenital and represent
single or multiple enzyme deﬁciencies, which if left untreated
can lead to life threatening conditions, with a current incidence
rate of 1 : 800 live births.1 IEMs can be grouped into three
diagnostically meaningful groups:2 (i) disorders giving rise to
intoxication, via accumulation of intracellular compounds over
time, (ii) disorders involving energy metabolism, and (iii) disorders
involving metabolism of complex molecules (Fig. S1, ESIz).
Moreover, IEMs can be present at any age – from fetal life to
old age – and the symptoms vary between the groups as well as
within the groups. Not all IEMs can be easily diagnosed, and
treatment does not exist for many of them, although many
disorders of the ﬁrst group can now be treated by changing the
patient’s diet.2 In recent years, numerous reviews have been
published analyzing IEMs from various aspects, including
newborn screening programs and systems biology,3–5 high-
lighting their importance and the general interest in under-
standing the molecular basis of IEMs.
The use of tandem mass spectrometry (MS/MS) has enabled
improvements in metabolic screening methods to more reliably
detect IEMs among newborns with a low false positive rate.6
Newborn screening is mandatory in most countries; however,
the measured biomarkers diﬀer signiﬁcantly between them, with
42 (20 primary and 22 secondary disorders) metabolic condi-
tions screened for newborn screening in some states within the
USA and countries participating in the Stork program (Iceland
being one of the participating country).7,8 The substantial
increase in the number of patients diagnosed with IEMs4,9 can
be majorly attributed to improved and standardized measure-
ments of amino acids and acylcarnitine concentrations.7,10 For
the diagnosis of some IEMs, ratios of biomarker provide more
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insight about pathological states than absolute biomarker
concentrations (e.g., tyrosine to phenylalanine ratio for the
diagnosis of phenylketonuria, OMIM: 261600).
Fatty acid oxidation defects are highly prevalent IEMs with
a collective incidence rate of 1 : 9000.11 In the case of infants,
fatty acid oxidation serves as energy source within the ﬁrst
12 hours of fasting; thus, they are more likely to manifest fatty
acid oxidation defects.12 Acylcarnitines tend to rise in blood
and urine on the ﬁrst day of the birth and then decline
gradually.6 By proﬁling numerous acylcarnitines, MS/MS
technology has expanded the range of detection for fatty acid
disorders (e.g., of medium chain acyl-CoA dehydrogenase
deﬁciency) and for organic acid disorders (e.g., propionic
academia and glutaric aciduria type-I).
Metabolic network reconstructions are assembled in a
bottom-up approach based on genome annotation, biochemical,
and physiological data.13 They summarize current knowledge
about the target organism in a structured, stoichiometric manner.
In many cases, manual curation including in-depth literature
search is performed to ensure high quality and coverage of the
reconstruction.14 Once reconstructed, metabolic networks can be
queried for their biochemical information, be employed to map
various data types (e.g., transcriptomic data or metabolomic
data), or serve as a starting point for computational modelling
(see ref. 15 for a recent review).
Results and discussion
The aim of this study was to compile a compendium of IEMs that
map onto the available reconstruction of human metabolism16 to
enable the analysis of IEMs in a metabolic modelling context
(Fig. 1). Therefore, we ﬁrst reconstructed the fatty acid oxidation
pathways to enable the mapping of routinely measured
acylcarnitines, which were missing in the published reconstruction
of human metabolism.16 Subsequently, we mapped IEMs onto
the expanded humanmetabolic network based on known aﬀected
genes, and assembled important phenotypic and clinical features
of each IEM. Finally, we investigated the IEMs in the context of
the expanded human metabolic reconstruction by identifying
IEMs, which shared reactions and metabolites, therefore,
representing hot spots in human metabolism.
Detailed reconstruction of acylcarnitine metabolism
In this study, we employed the published human metabolic
reconstruction, Recon 1,16 as a starting point for the acyl-
carnitine and fatty acid oxidation (AC/FAO) reconstruction
module. The human metabolic reconstruction accounts for
metabolic reactions occurring in any human cell, as deﬁned by
the human genome. As such, the reactions present in Recon 1
may not occur in all cells, but a particular cell type may only
express a subset of metabolic enzymes captured by Recon 1.
For example, the liver completely detoxiﬁes ammonia to urea via
urea cycle, however, in kidney the urea cycle is only partially
active, i.e., kidney accounts for arginine synthesis. The majority
of the reactions are mass and charge balanced, and many of
them are assigned with structured Boolean relationships
between genes, proteins, and reactions. Recon 1 captures all
amino acids (except methylhistidine) measured in the newborn
screening but it only accounts for the metabolism of six of
the 39 acylcarnitines (Table S1, ESIz). Moreover, Recon 1
accounts for most of the relevant reactions in beta fatty acid
oxidation, while alpha and omega fatty acid oxidation reac-
tions are only partially captured. After collecting supporting
evidence from more than 150 peer reviewed articles and books,
we reconstructed an AC/FAO module that accounts for 352
reactions, 139 metabolites, and 14 genes, with the reactions
distributed within the endoplasmic reticulum, peroxisomes,
mitochondria, and cytosol (Fig. 2B). The majority of the
reactions are involved in fatty acid metabolism (Fig. 2A).
Note that this reconstruction module is only functional in
conjunction with Recon 116 or its successor.17
Acylcarnitines in the AC/FAO module. The AC/FAO module
accounts for 39 acylcarnitines routinely measured in newborn
screening (Table S1, ESIz), which include dicarboxylic-
acylcarnitines, hydroxy-acylcarnitines, and other short chain acyl-
carnitines (Fig. 2B). For instance, succinylcarnitine, a four carbon
fatty acid is a dicarboxylic-acylcarnitine and generated via the
valine, isoleucine and methionine pathway. Hydroxy-isovaleryl-
carnitine is a ﬁve carbon fatty acid attached to a carnitine moiety,
has a hydroxy group at the third carbon atom and is generated via
the leucine pathway. These two dicarboxylic-acylcarnitines are
used as biomarkers for organic acidemias and more recently also
for biotin deﬁciency.18–20 A total of ﬁve reactions were added
describing the synthesis of succinylcarnitine and hydroxy-
isovalerylcarnitine, and subsequent processing by the carnitine
palmitoyltransferase 1 enzyme (CPT-1, E.C. 2.3.1.21), which is
encoded by three gene isoforms CPT1A (GeneID: 1374), CPT1B
(GeneID: 1375), and CPT1C (GeneID: 126129). Another
dicarboxylic-acylcarnitine is glutarylcarnitine, which is an
important biomarker in glutaric aciduria,21,22 generated as
an intermediate in lysine and tryptophan metabolism. Like-
wise, 3-hydroxy-butyrylcarnitine, a hydroxy-acylcarnitine and
biomarker for short-chain-acyl-CoA-dehydrogenase deﬁciency,23
is generated via butanoate metabolism. Hydroxyacylcarnitines
generally serve as biomarkers for several mitochondrial fatty acid
beta oxidation disorders.24
Other short chain acylcarnitines include acetylcarnitine,
tiglylcarnitine, and isovalerylcarnitine. Acetylcarnitine is pro-
duced from acetyl-CoA, which is an important end product of
fatty acid oxidation, ketogenic amino acid metabolism, and a
precursor of cholesterol metabolism. An increased level of
acetylcarnitine may reﬂect CPT-2 deﬁciency.25 Tiglylcarnitine
and isovalerylcarnitine are intermediates of isoleucine and leucine
metabolism, respectively, and are formed from their respective
precursor fatty acyl-CoAs, tiglyl-CoA and isovaleryl-CoA, by
the action of the CPT-1 enzyme. These short chain acylcarnitines
are biomarkers for methylacetoacetyl-CoA deﬁciency, iso-
valeric acidemia, and short-chain acyl-CoA dehydrogenase
deﬁciency.26–28 The metabolic reactions of these important
short chain acylcarnitines were added to the AC/FAO module.
Addition of carnitine shuttle to mitochondria and ABC transport
reactions to the peroxisome. Speciﬁc transporters are required to
deliver acyl-CoAs to their destined sub-cellular compartments for
their oxidation. The three step carnitine shuttle system trans-
ports acyl-CoAs into the mitochondrion and this transport is
reversible.29 It involves reactions catalyzed by the CPT-1 enzyme,
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the carnitine/acylcarnitine translocase protein (SLC25A20,
GeneID: 788) and the carnitine O-palmitoyltransferase 2
(CPT2, GeneID: 1376, E.C. 2.3.1.21). The transport is aﬀected
in some IEMs, such as the carnitine uptake defect, CPT-1
deﬁciency, and CPT-2 deﬁciency.29 The AC/FAO module
contains a reﬁned carnitine shuttle system with 38 reactions
accounting for the reversible transport of a wide range of
metabolites. Peroxisomes contain ATP-dependent transporters
for the import of very long chain acyl-CoAs (Fig. 2B).30 A total
of ten ABC transport reactions and their associated genes were
identiﬁed, including three genes of the ATP-binding cassette
superfamily (ABCD1, GeneID: 215; ABCD2, GeneID: 225;
ABCD3, GeneID: 5825). The human metabolic reconstruction
accounts for the transport of 4,8-dimethylnonanoyl-CoA by the
carnitine O-octanoyltransferase (CROT, GeneID: 54677, E.C.
2.3.1.137). The same protein also transports butyryl-CoA and
hexanoyl-CoA into the peroxisome.29 We included this extended
substrate speciﬁcity in the AC/FAO module.
Addition of new fatty acid oxidation genes
To capture all fatty acid oxidation related IEMs, 84 mitochondrial
beta-oxidation reactions and 63 metabolites were added to the
AC/FAOmodule. We also added the necessary genes and their
respective gene products, including hydroxyacyl-CoA dehydro-
genase (HADH, GeneID: 3033, E.C. 1.1.1.35) and the acetyl-
CoA acyltransferase 2 (ACAA2, GeneID: 10449, E.C. 2.3.1.16),
which have substrate speciﬁcity for short and medium chain
acyl-CoAs and catalyze the dehydrogenation and thiolytic
cleavage step, respectively.31 The 2,4-dienoyl-CoA reductase 1
(DECR1, GeneID: 1666, E.C. 1.3.1.34) was another auxiliary
enzyme of the mitochondrial beta-oxidation of unsaturated acyl-
CoAs that was missing in the human metabolic reconstruction.
The addition of these three genes enabled the mapping of further
ﬁve IEMs (Table S2, ESIz). Moreover, four additional genes
were added to the AC/FAOmodule, whose products are mainly
involved in activation and transport of fatty acids.32,33 These
were fatty acid transporter (SLC27A6, GeneID: 28965),
bubblegum (ACSBG1, GeneID: 23205, E.C. 6.2.1.3), bubblegum
related protein (ACSBG2, GeneID: 81616, E.C. 6.2.1.3), and
diazepam binding inhibitor (DBI, GeneID: 1622).
Long and very long chain acyl-CoAs are oxidized in peroxisome
before entering the mitochondrion.34,35 Therefore, 66 peroxisomal
beta-oxidation reactions and 59 metabolites were included in the
AC/FAO module (Fig. 2B) permitting the mapping of X-linked
adrenoleukodystrophy (OMIM: 300100), acyl-CoA oxidase-1
(OMIM: 264470), and D-bifunctional-protein deﬁciencies
(OMIM: 261515). The peroxisome contains the complete
enzymatic machinery for handling unsaturated fatty acids.36,37
In the human metabolic reconstruction, important auxiliary
proteins, reactions, and their respective genes were missing
and were thus included in the AC/FAO module. This addition
comprises the functions of the peroxisomal 2,4-dienoyl-CoA
reductase 2 (DECR2, GeneID: 26063, E.C. 1.3.1.34) and
the enoyl-CoA delta isomerase 2 (PECI, GeneID: 10455,
E.C. 5.3.3.8).
Alpha oxidation of phytanic acid was also reconstructed in
detail in the AC/FAO module (Fig. 2B). Two new genes and
Fig. 1 Overview of the workﬂow that we used in this study. The metabolites, which are measured in the newborn screening program, were identiﬁed
along with their chemical names, chemical formula, charge, normal physiological concentration, and related IEMs. These metabolites were then
mapped onto Recon1, using name and formula, which led to the mapping of 20 amino acids and six acylcarnitines. For the remaining metabolites
(i.e., 33 acylcarnitines), which could not be mapped, we reconstructed their respective metabolic pathways based on the literature, and added the
corresponding reactions to the AC/FAO module. Subsequently, we combined the AC/FAO module with Recon 1, resulting in Recon1_AC/FAO.
Thereafter, we employed the information retrieved from the literature to map the IEMs onto this extended reconstruction. A total of 235 IEMs could
be mapped and subsequently classiﬁed along with their diﬀerent physiological and clinical features. Another set of 139 IEMs were identiﬁed, termed
as future IEMs, which could not be mapped onto Recon1_AC/FAO due to missing genes in the reconstruction. These 374 IEMs constitute the IEM
compendium, which we mapped onto the human metabolic network to obtain a holistic network perspective of the captured IEMs.
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the reactions catalyzed by the respective gene product were
added: fatty acid transporter (SLC27A2, GeneID: 11001,
E.C. 6.2.1.-) and phytanoyl-CoA 2-hydroxylase 1 (HACL1,
GeneID: 26061, E.C. 4.1.-.-). Reduced activity of the SLC27A2
transporter protein has been reported to be responsible for the
biochemical pathology in X-linked adrenoleukodystrophy in
mouse models.38 Omega oxidation is important for the genera-
tion of dicarboxylic acids; therefore, eight reactions were added
to AC/FAO (Fig. 2B).
Detailed reconstruction of fatty acid oxidation reactions.
The long chain fatty acids were only partially captured in
the human metabolic reconstruction. Gene-protein-reaction
(GPR) associations for three acyl-CoA dehydrogenases: C-2
to C-3 short chain (ACADS, GeneID: 35, E.C. 1.3.99.2), C-4
to C-12 straight chain (ACADM, GeneID: 34, E.C. 1.3.99.3),
and very long chain (ACADVL, GeneID: 37, E.C. 1.3.99.-),
were incorporated according to their substrate speciﬁcities. We
also added the reactions catalyzed by the trifunctional hydroxy-
acyl-CoA dehydrogenase (HADHA, GeneID: 3030 and
HADHB, GeneID: 3032; E.C. 4.2.1.17/1.1.1.211/ 2.3.1.16),31
which catalyses the steps after desaturation of long acyl-CoAs
(>14 carbon units). The mitochondrial short chain enoyl-
CoA hydratase 1 (ECHS1, GeneID: 1892, E.C. 4.2.1.17)
catalyzes the hydration step for medium and short chain fatty
acyl-CoAs, but in Recon 1, the gene product catalyzes only
reactions involved in tryptophan and beta-alanine meta-
bolism. Hence, the hydration steps are needed to be added
to account for the relevant fatty acid oxidation reactions. We
also expanded the substrate speciﬁcity of the enoyl-CoA delta
isomerase 1 (DCI, GeneID: 1632, E.C. 5.3.3.8), which has only
one reaction associated in Recon 1. These comprehensive
additions to the fatty acid oxidation pathway enabled the
mapping of numerous IEMs, including peroxisomal acyl-CoA
oxidase deﬁciency/adrenoleukodystrophy pseudoneonatal
(OMIM: 264470), Zellweger syndrome, neonatal adreno-
leukodystrophy and infantile Refsum disease, D-bifunctional
protein deﬁciency (OMIM: 261515), and pseudo-Zellweger
syndrome.
All enzymes involved in omega oxidation were present in
Recon 1, but catalyzed only reactions involving either xeno-
biotic or eicosanoid metabolism, while reactions of the omega
oxidation of fatty acids were missing. The AC/FAO module
accounts for all known reactions of the omega oxidation
Fig. 2 General properties of the AC/FAO module. (A) Overview of the fatty acid oxidation pathways, along with their deﬁnitions, substrate
preferences, key steps involved, and associated disorders. (B) Schematic map of the key reactions in the AC/FAO module and their sub-cellular
location. The numbers indicate the number of reactions per metabolic pathway. The substrates for the omega oxidation pathway are very long
chain fatty acids and long chain fatty acids, while the products are dicarboxylic acids, which further undergo beta oxidation in the peroxisome.
Phytanic acid, which is a substrate for the alpha fatty acid oxidation, produces pristanic acid. This product is further beta-oxidized in the
proxisomes before ﬁnally entering the mitochondrion. The fatty acyl-CoAmolecules are transported between the peroxisomes and mitochondria in
the form of acylcarnitines, and once inside the mitochondria they may either undergo complete beta oxidation generating acetyl-CoA (in the case
of even chain fatty acid) or propionyl-CoA (in the case of odd chain fatty acid) and ﬁnally produce energy through the oxidative phosphorylation
in the mitochondria. However, if the beta oxidation is incomplete, it produces hydroxy fatty acids, which are then shuttled out of the
mitochondrion as acylcarnitines. Substrates for peroxisomal beta oxidation are long chain and vary long chain fatty acids entering the peroxisome
via an ATP dependent transport system. Short, medium, and long chain fatty acids enter mitochondria as acylcarnitines. (C) Key characteristics of
Recon 1 and Recon1_AC/FAO. A reversible version of the Recon 1 reactions, i.e., 64 reactions of the carnitine shuttle system, was also added
(not shown here, see Table S9 and supplement text for details). *Taken from ref. 103. **Corresponds to primary literature, peer review articles,
and books that were used only for the acylcarnitine reconstruction. Abbreviations used: FA – fatty acid; PUFA – poly unsaturated fatty acid;
ER – endoplasmic reticulum; FAO – fatty acid oxidation; VLCFA – very long chain fatty acid; LCFA – long chain fatty acid; MCFA – medium
chain fatty acid; SCFA – short chain fatty acid; C2 – acetyl-CoA; C3 – propionyl-CoA.
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pathway39–43 along with the relevant GPR association, linking
the corresponding genes to these reactions. The participating
genes include the cytochrome P450 family genes (CYP4F2,
GeneID: 8529, E.C. 1.14.13.30; CYP4F3, GeneID: 4051, E.C.
1.14.13.30), the aldehyde dehydrogenase 3 family (ALDH3A2,
GeneID: 224, E.C. 1.2.1.3), the alcohol dehydrogenase (ADH5,
GeneID: 128, E.C. 1.1.1.1), and the acyl-CoA synthetase
(ACSL5, GeneID: 51703, E.C. 6.2.1.3). A detailed description
of all fatty acid oxidation pathways is provided in ESI.z
Mapping of inborn errors of metabolism onto the human
metabolic reconstruction
A major aim of this study was to create a comprehensive
compendium of IEMs that maps onto the human metabolic
reconstruction. We therefore joined our AC/FAO module
with the published human metabolic reconstruction (Recon
1)16 and called this extended network Recon1_AC/FAO. To
map defective genes (i.e., gene mutations that cause an IEM)
reported in the literature and databases for the various IEMs
to reactions, we employed the GPR associations deﬁned for
the 1510 metabolic genes accounted for in Recon1_AC/FAO.
After extensive literature search, we identiﬁed 235 IEMs,
which had all causal genes captured in Recon1_AC/FAO
(Table S2, ESIz). In 139 cases, not all genes known to cause
an IEM were present in the reconstruction and we collected
them in a separate list (Table S3, ESIz), which represents a
starting point for future extension and gap ﬁlling of function-
alities included in the human metabolic reconstruction.44,45
The following information was retrieved for each IEM from
the literature and databases: aﬀected organs, mode of inheri-
tance, biomarkers, biomarker concentrations, and phenotype.
While we illustrate some interesting cases below, a complete
list of mapped IEMs and all relevant information can be found
in Table S2, ESI.z
Pathway classiﬁcation. The 235 mapped IEMs could be
grouped into 16 diﬀerent central metabolic pathways (Fig. 3A).
The highest number of IEMs was found to be in carbohydrate
metabolism (65), followed by amino acid metabolism (54), and
lipid metabolism (51). Carbohydrate metabolism includes a
wide range of metabolic pathways, more so, since we counted
also glycoprotein and glycolipid metabolism to this subsystem.
Moreover, this class of inherited disorders is well studied.46
The 235 IEMs were caused by defects in 250 unique metabolic
genes, which encode enzymes catalyzing 1067 reactions in total
(this includes 750 unique and 317 shared metabolic reactions).
A similar distribution pattern was observed for the aﬀected
genes, when categorizing them according to their biochemical
pathway. The higher number of reactions relative to the
number of genes was caused by the broad substrate speciﬁcity
of many enzymes, which was particularly true for enzymes
involved in the fatty acid oxidation metabolism. This analysis
highlights that a systems biology modelling approach may
facilitate signiﬁcantly the assessment of an IEM’s contribution
to its global metabolic phenotype.
Mode of inheritance and phenotype analysis. IEMs follow a
particular mode of inheritance.47 We grouped the IEMs based
on ﬁve diﬀerent modes of inheritance: (i) autosomal recessive,
(ii) autosomal dominant, (iii) autosomal recessive or auto-
somal dominant (as seen in hypophosphatasia, OMIM:
241500, OMIM: 241510, and OMIM: 146300), (iv) X-linked
or autosomal dominant (as seen in familial gynecomastia,
OMIM: 139300 and OMIM: 107910), and (v) X-linked pattern
(X-linked recessive and X-linked dominant IEMs treated as
one mode, i.e., X-linked pattern) (Table S2 and S4, ESIz).
Inheritance patterns were identiﬁed for 199 (61%) of the
IEMs, as the majority of the remaining IEMs have not been
studied suﬃciently or have been only identiﬁed in very few
individuals so that the pattern of inheritance could not be
established. This latter group includes acetyl-CoA carboxylase
deﬁciency (OMIM: 200350), AICA-ribosiduria (OMIM:
608688), and hepatic lipase deﬁciency (OMIM: 151670). The
majority of the IEMs with the reported inheritance pattern
were autosomal recessive (163 IEMs, 82%).
IEMs can also be classiﬁed according to the number of
phenotypic patterns observed. Diﬀerent phenotypes arise due
to modiﬁer genes, allelic variations, complex genetic and
environmental interactions, or environmental factors. There-
fore, speciﬁc eﬀects may be seen at diﬀerent age (i.e., appear-
ance of speciﬁc morphological features), or may lead to
diﬀerence in the severity of the disorder.48,49 We were able
to collect such information for 90 IEMs (38%) (Table S2 and
S5, ESIz). The majority of these IEMs present two phenotypic
forms. For example, a classic form and a mild form (e.g., in
medium chain acyl-CoA dehydrogenase deﬁciency, OMIM:
201450), an acute and a chronic form (e.g., in isovaleric academia,
OMIM: 243500), an early and a delayed onset (e.g., in carbamoyl
phosphate synthetase I deﬁciency, OMIM: 237300), a severe and
a moderate form (e.g., in glucose-6-phosphate dehydrogenase
deﬁciency, OMIM: 305900), a type 1 and a type 2 form (e.g., in
3-methylcrotonyl-CoA carboxylase deﬁciency, OMIM: 210200
and OMIM: 210210). Other IEMs have a more complex
phenotypic pattern (Table S2, ESIz).
Organ classiﬁcation. Clinical manifestations observed in
aﬀected patients with particular IEMs were also noted.
A total of 28 organ systems were aﬀected in 217 distinct IEMs.
Most of the remaining IEMs, such as essential pentosuria
(OMIM: 260800), erythrocyte AMP deaminase deﬁciency
(OMIM: 612874), and acatalasemia (OMIM: 115500), present
no apparent clinical dysfunction. As one may expect, the
organ systems were not equally aﬀected by IEMs (Fig. 3B).
A criterion for calling an organ ‘aﬀected’ was either (i) when a
clinical sign was reported by a clinical practitioner (e.g., tongue
in mucopolysaccharidosis VI, OMIM: 253200), (ii) when a
symptom was described by the patient, (iii) an identiﬁed
pathological report, (iv) an established biochemical defect
(e.g., kidneys in renal glucosuria, OMIM: 233100, due to
inability of the renal tubules to reabsorb glucose), or (v) a
combination of these criteria. For example, cherry red spot
signs on the eye have been reported as abnormal feature in
Sandhoﬀ disease (OMIM: 268800) and Tay–Sach’s disease
(OMIM: 272800); thus, the eye was noted as being aﬀected.
For some IEMs, organs can be aﬀected at a later stage, as it is
the case for the CPT-2 deﬁciency (lethal neonatal form,
OMIM: 608836), where postmortem examination showed diﬀuse
lipid accumulation in the liver, heart, kidneys, adrenal cortex,
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skeletal muscle, and lungs. In these cases, the aﬀected organs
were noted based on these data. Certain organs, such as the
liver, pancreas, bile canaliculi, and gall bladder were deliber-
ately treated separately from the digestive system since these
organs are speciﬁcally aﬀected in certain disorders without
involvement of the digestive system as a whole. For example,
glycogen storage disease type 6/Hers disease aﬀects only the
liver,50 while the HMG-CoA lyase deﬁciency (OMIM: 246450)
aﬀects only liver and pancreas and the familial hypercholanemia
(OMIM: 607748) aﬀects the liver and bile canaliculi. The
category digestive systemmainly represents the small and large
intestine in our classiﬁcation scheme. The nervous system
includes the central nervous system and the peripheral nervous
system. The nervous system was also deemed to be aﬀected in
IEMs with hypotonia as a clinical sign (e.g., in 3-methylcrotonyl-
CoA carboxylase deﬁciency, propionic academia, and aromatic
L-amino acid decarboxylase deﬁciency51) since hypotonia, or
reduced muscle tone, is related to motor nerve dysfunction,
which is controlled by the brain. Using this classiﬁcation
scheme, we found the nervous system to be the most com-
monly aﬀected organ by IEMs. This result can be explained in
part on the basis that in almost all aminoacidopathies (second
most prevalent category of IEMs, Fig. 3A), blood concen-
tration of one or more amino acids is increased, which then
competitively inhibits the transport of essential amino acids
across the blood–brain-barrier.52 Amino acids and their impor-
tant derivative metabolites also serve as neurotransmitters,
which are serine (produces the choline part of acetylcholine),
tyrosine (produces L-3,4-dihydroxyphenylalanine, dopamine,
and catecholamines), tryptophan (produces serotonin), glycine,
glutamate (produce gama-aminobutyric acid), and histidine
(produces histamine). In many aminoacidurias, there may be
Fig. 3 Distribution of IEMs based on various properties. (A) The 235 IEMs mapped onto Recon1_AC/FAO were categorized into 16 diﬀerent
metabolic categories. The comparison between the number of IEMs (black), number of genes (white), and number of reactions (grey) per IEM
category is plotted on a logarithmic scale. A total of 250 unique genes encode for gene products catalyzing 750 unique metabolic reactions, which
are aﬀected in at least one IEM. (B) Percentage of IEMs that aﬀect diﬀerent organ systems. For simplicity we only show highly aﬀected organs.
D
ow
nl
oa
de
d 
by
 S
ta
nf
or
d 
U
ni
ve
rs
ity
 o
n 
15
 Ju
ne
 2
01
2
Pu
bl
ish
ed
 o
n 
02
 M
ay
 2
01
2 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C2
MB
250
75F
View Online
This journal is c The Royal Society of Chemistry 2012 Mol. BioSyst.
observed deﬁcits of neurotransmitters, particularly of N-methyl-
D-aspartate, and of their receptors.52 Furthermore, low levels
of N-acetylaspartate and high levels of lactate in the brain,
besides high levels of branched chain amino acids in both the
brain and blood, are observed during metabolic de-compensation,
and indicate mitochondrial dysfunction leading to brain
energy failure.53,54 These examples illustrate how a defective
amino acid metabolism can dramatically aﬀect the nervous
system. The category ‘muscles’ includes skeletal and smooth
muscles but not cardiac muscles, since we considered the heart
as a separate organ category. Carbohydrates and lipids pro-
vide energy to muscles while amino acids help in forming
muscle proteins, which explains why these metabolic pathway
defects aﬀect muscle function. The liver is the central meta-
bolic unit of the human body accounting for majority of the
biochemical transformations. A disturbance in any metabolic
pathway will eventually aﬀect the liver’s function. Energy
supply of the heart is mostly provided by fatty acids; however,
glucose, lactate, ketone bodies, and amino acids are also used
in diﬀerent proportions.55
Biomarker classiﬁcation. Enzyme assays, which test for
enzyme activity, and identiﬁcation of speciﬁc mutations, are
frequently used as diagnostic tools for IEMs.2 The diagnosis of
IEMs experienced a tremendous rise with the advent of high-
throughput detection techniques, such as mass spectrometry.56
Metabolic biomarkers arise due to the presence of an IEM and
are extensively used for diagnosis. For example, a disease
either causes accumulation of a biomarker (e.g., elevated
triglycerides in Tangier disease, OMIM: 205400) or the
decrease/absence of a speciﬁc metabolite (e.g., carnitine in
the carnitine uptake defect, OMIM: 212140). In fact, 17 diﬀerent
metabolites are used as biomarkers for the diagnosis of 130 of
the 235 IEMs (Fig. S2, ESIz). Metabolic biomarkers are, of
course, acylcarnitines and amino acids, which also include
amino acid derivatives, such as 5-oxoproline, 3-methoxy-
tyrosine, and 5-hydroxytryptophan, but also include the other
classes of compounds (see Table S2 (ESIz) for a complete list).
For example, carbohydrates account for a variety of com-
pounds, most notably dolichol, oligosaccharides, galactitol,
galactose, glucose, xylulose, arabitol, ribitol, glycogen, and
glycan molecules. Cholesterol includes free and esteriﬁed
cholesterol and its steroid derivatives (lipoproteins like HDL-
cholesterol). Fatty acids include both straight and branched
chain fatty acids as well as their derivatives, such as 2-ethyl-
3-keto-hexanoic acid and 3-hydroxyisovaleric acid. The lipids
class includes, for example, triglycerides, prostagladins
(leukotrienes), and glycerol. The organic acids class represents
a wide range of compounds, such as glycolic acid, glyoxylic
acid, glyceric acid, and oxalic acid (see Table S2 (ESIz) for the
detailed classiﬁcation scheme).
To assess the use of diﬀerent metabolic biomarkers and
enzyme assays employed for diagnosis of IEMs, we compared
the reported biomarkers across the mapped IEMs. We found
that enzyme assays are used for the diagnosis of 34% of the
mapped IEMs (Fig. S2, ESIz). Moreover, we found that the
measurement of amino acid and acylcarnitine concentrations are
primary laboratory tests, followed by tests for carbohydrates,
organic acids, and fatty acids. In fact, acylcarnitine proﬁling is
one of the emerging trends57 due to the numerous roles of carnitine
in the body.58 Abnormal concentrations of acylcarnitines may
indicate aminoacidopathies, fatty acid oxidation defects, and
organic acid disorders. However, the absence of acylcarnitine
abnormalities does not rule out disorders and needs to be
conﬁrmed by enzyme assays.57 Moreover, all diagnostic criteria
need conﬁrmation for the presence of known mutations in the
corresponding gene(s).57,59,60 The DNA analysis may serve
as sole diagnostic test for some IEMs, including infantile
neuroaxonal dystrophy (OMIM: 256600) and leber congenital
amaurosis type 3 (OMIM: 612712).
Types of therapies. Six diﬀerent types of therapies are used
to treat 158 of the 235 mapped IEMs (67%) (Table S6, ESIz).
The diﬀerent therapeutic measures include dietary inter-
ventions, medications, organ transplantation, enzyme replace-
ment therapy, and gene therapy. Enzyme replacement therapy
is used to treat, for example, adenosine deaminase deﬁciency
(OMIM: 102700), Fabry disease (OMIM: 301500), Pompe
disease (OMIM: 232300), and mucopolysaccharidosis type
VI/Maroteaux–Lamy syndrome (OMIM: 253200). Organ
transplantation usually involves either bone marrow trans-
plant or a speciﬁc organ, and is generally employed in cases of
mucopolysaccharidosis type I (OMIM: 607014) and methyl-
malonic academia.61 So far, enzyme replacement therapy has
been promising, e.g., for lysosomal storage disorders, while
organ transplantation has only shown limited success due to
graft rejection.2 Additionally, gene therapy depends on the
possible extent and duration of the gene expression without
leading to toxicity.2 On the other hand, dietary measures and
speciﬁc medications have been preferred methods for the
treatment of many IEMs. Therefore, we considered diet
and medications as separate categories for IEMs, which are
treated solely by these measures (see Table S2 (ESIz) for a
complete list).
Functional network view of the IEM compendium
The combined Recon1_AC/FAOmetabolic network accounted
for 3032 metabolites, 4095 reactions, and 1919 transcripts,
corresponding to 1510 unique genes, with metabolites and
reactions distributed over eight compartments (Fig. 2C). We
investigated the 235 mapped IEMs from a functional network
topology perspective. First, we determined the number of
reactions associated with each IEM (Fig. 4A). Interestingly,
six IEMs were associated with more than 50 reactions each in
Recon1_AC/FAO (Table S2, ESIz), including CPT-1 deﬁ-
ciency and Zellweger syndrome (both having 71 reactions
associated with their respective defective genes). These IEMs
with high reaction association represent hubs in the metabolic
network, which are expected to have a great impact on the
network functionality when perturbed. In fact, many of these
IEMs are known to have a severe phenotype (Table S2, ESIz).
While 97 (41%) of the IEMs had only one reaction associated,
we were interested in whether there were any IEMs, which had
multiple associated reactions, that shared reactions and
exhibited similar or overlapping phenotype. We identiﬁed
53 IEM pairs, consisting of 52 unique IEMs, which share at
least one metabolic reaction in Recon1_AC/FAO. The reac-
tion overlap, and potential similarities of disease phenotypes,
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may also hamper the diagnosis of these IEMs. At the same
time, this network driven view on IEMs permits us to correlate
diseases that may not be associated with each other otherwise.
We were particularly interested in those IEMs that had all
reactions in common since these IEMs and knowledge about
their phenotypes and biomarkers could be used in subsequent
studies to assess the model’s predictive capabilities and may
also underline the importance of tissue- and cell-type speciﬁc
reconstructions for metabolic modelling.
Furthermore, we identiﬁed seven reaction pairs in Recon1_AC/
FAO that shared all reactions (Table 2). Interestingly,
these IEM pairs also shared clinical features. For example,
the Tay–Sachs disease (OMIM: 272800) and the Sandhoﬀ
disease (OMIM: 268800) are caused by a defect in the
Fig. 4 Network properties of the IEM compendium. (A) The graphic shows the number of reactions aﬀected per IEM (rank ordered). We used
the gene-protein-reaction associations present in Recon1_AC/FAO to determine the number of reactions catalyzed by enzymes in Recon1_AC/
FAO that is known to be deﬁcient in IEMs (see also Table S2, ESIz). (B) Many IEMs are connected in the metabolic reconstruction through shared
metabolites. We use the highly connected, important central metabolite acetyl-CoA to illustrate the metabolic connectivity of the IEMs (shown
adjacent to the respective metabolisms) within the human metabolic network. Malonyl-CoA, which is formed from acetyl-CoA via the action of
acetyl-CoA carboxylase (E.C. 6.4.1.2), participates in fatty acid synthesis, and a potent inhibitor of CPT-I enzyme (E.C. 2.3.1.21). Malonyl-CoA
levels are regulated by malonyl-CoA decarboxylase (E.C. 4.1.1.9). All together, these enzymes maintain ﬁne-tuning between fatty acid breakdown
and synthesis.
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beta-hexosaminidase (E.C. 3.2.1.52).62 The beta-hexosaminidase
catalyzes the glycosyl bond hydrolysis, thus removing amino
sugars from the non-reducing ends of oligosaccharides.63 Three
forms of the enzyme have been described (A, B, and S) with
distinct structures and subunit compositions.64 The gene HEXA
(Gene ID: 3073) encodes the alpha subunit, whereas the gene
HEXB (Gene ID: 3074) encodes the beta subunit of the enzyme.
Though diﬀerent mutations in these two genes lead to Tay–Sachs
disease and Sandhoﬀ disease, these diseases are clinically
indistinguishable (OMIM: 268800).65 Nonetheless, a mouse
model study has reported diﬀerences in phenotypes.66 Another
interesting case was the IEM pair of sialidosis (OMIM:
256550) and Morquio syndrome (OMIM: 253000), which are
both defects in carbohydrate metabolism and exhibit similar
neurologic abnormalities67 (Table 2).
The network view of IEM compendium does not only allow
us to determine reactions that are shared between IEMs but
also assists in the systematic identiﬁcation of IEMs, which are
connected through common metabolites. This analysis was
triggered by the observation that many IEMs were adjacent on
the metabolic map (Fig. 5). Metabolic connectivities between
IEMs may also highlight co-morbidities.68 When excluding
highly connected metabolites, such as adenosine triphosphate,
water, and protons, we found that acetyl-CoA in particular
acted as a common link between the metabolic pathways,
which is a well-known fact in biochemistry. Acetyl-CoA is
(i) used to acetylate various metabolites, including polyamines,
(ii) generated as an end-product of leucine and isoleucine
catabolism, (iii) a precursor for cholesterol and fatty acid
synthesis, and (iv) required to form N-acetyl-glutamate, which
is an allosteric activator of carbamoyl-phosphate-synthase-I
(E.C. 6.3.4.16) catalyzing the ﬁrst reaction of the urea cycle.69
Under normal physiological conditions, acetyl-CoA enters the
TCA cycle after being produced by beta fatty acid oxidation.
However, under prolonged fasting conditions, acetyl-CoA
enters ketone body synthesis, and they appear in urine.69,70
Our network-based analysis further revealed that acetyl-CoA
serves a hub linking diﬀerent important IEMs (Fig. 4B),
whereas the metabolic fate of acetyl-CoA varies depending
on pathways and pathophysiological conditions.
Simulation of phenylketonuria with the metabolic model of
Recon1_AC/FAO
Phenylketonuria (PKU, OMIM: 261600) is caused by muta-
tions in PAH (GeneID: 5053) that may lead to complete or
partial loss of the phenylalanine hydroxylase activity (E.C.
1.14.16.1). The enzyme catalyzes hydroxylation of phenylalanine
to tyrosine (Table 1). We chose PKU to demonstrate how a
model derived from Recon1_AC/FAO can be used to simulate
enzymopathies and to predict potential changes in bioﬂuid
concentrations. Therefore, we deleted the model reactions asso-
ciated with the PAH gene, as deﬁned through the GPRs, to
simulate the consequences of complete loss of enzyme activity.
The model was allowed the uptake and secretion of all meta-
bolites with deﬁned exchange reactions. We then performed ﬂux
balance analysis,71 where the exchange reaction for L-tyrosine or
L-phenylalanine was used as an objective function. As expected,
L-tyrosine secretion rate was zero in the PKU model, while
L-tyrosine secretion was possible in the model corresponding to
the healthy state. This result is consistent as PKU patients
usually have low plasma tyrosine levels (OMIM: 261600), which
is most often seen due to low enzyme activity. In contrast, no
change in L-phenylalanine uptake or secretion was calculated in
the PKU model compared to the healthy model. Thus, the
model could not accurately represent the accumulation of
phenylalanine (in form of phenylalanine secretion), which
has been observed in plasma, urine, and cerebrospinal ﬂuid
Fig. 5 Visualization of 375 IEMs in our IEM compendium on the human metabolic map. This metabolic map, obtained from Kegg,104 gives an
overview of current knowledge about human metabolism based on the human genome and known biochemistry. We map the genes from
Recon1_AC/FAO (green), the genes underlying the 235 mapped IEMs (red), and the genes corresponding to the 139 uncharted IEMs (orange).
Note that 245 Recon1_AC/FAO genes and 55 uncharted IEM genes could not be mapped. The blue circles represent the diﬀerent amino acids and
acylcarnitines, which are routinely measured in the newborn screening program (see Table S1 (ESIz) for details). This map represents only a subset
of the metabolic pathways captured in Recon1_AC/FAO; we could only map 14 acyl-CoAs and 17 amino acids.
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of PKU patients (OMIM: 261600). The accumulation is due to
decreased utilization of phenylalanine by the phenylalanine
hydroxylase, while there is a continuous supply of dietary
phenylalanine. As we do not explicitly model the dietary
intake and human cells cannot synthesize phenylalanine, we
did not calculate increase in net phenylalanine secretion.
Conclusions
In this study, we generated an extended metabolic reconstruction,
Recon1_AC/FAO, which accounts for all metabolic and trans-
port reactions necessary to enable the mapping of biomarkers
measured in newborn screening programs.7,8 Furthermore, we
compiled a comprehensive compendium of 235 IEMs that have
all causal genes captured in Recon1_AC/FAO, containing also
important phenotypic, genetic, and clinical features for each IEM.
A challenge that we encountered during the reconstruction
process was the correct identiﬁcation of some acylcarnitines,
as MS/MS measurements do not always provide suﬃcient
chemical details about the unsaturated fatty acids (i.e., positional
isomers). To enable the inclusion of more metabolites and
corresponding reactions in the reconstruction, more precise
measurements are needed.
The IEMs of the compendium were categorized based on
diﬀerent criteria to assess to which extent they aﬀect whole
body and the global metabolism. For instance, the organ
classiﬁcation will be of additional value when tissue- and cell
type speciﬁc reconstructions and models are employed rather
than a generic human metabolic network. A current challenge in
computational modelling of metabolism is how one can generate
in a (semi-) automated manner tissue- and cell-type speciﬁc
reconstructions based on ‘omics’ data (e.g., transcriptomics).72
The organ classiﬁcation of IEMs could be used to further reﬁne
tissue-speciﬁc metabolic reconstruction. Moreover, as the
simulation of PKU highlighted, the use of a tissue-speciﬁc
model rather than the generic model derived from Recon1_AC/
FAO and more deﬁned boundary constraints will further
increase the predictive potential of the eﬀects of IEMs on
the overall metabolism and metabolite biomarkers.
In addition to the mapped 235 IEMs, we identiﬁed 139
‘uncharted’ IEMs (Table S3, ESIz), which could not be
mapped onto Recon1_AC/FAO due to missing genes. These
IEMs were classiﬁed under metabolic and non-metabolic IEMs
(e.g., causing a defect in regulatory or signalling pathways),
depending on the chief mechanism involved. The uncharted
metabolic IEMs will be a good starting point for further exten-
sion and reﬁnement of the human metabolic reconstruction. For
instance, the mapping of inherited disorders of lipid metabolism
will require further extension of the current human metabolic
reconstruction as only 51 IEMs of the lipid metabolism could be
mapped. Numerous new disorders have been identiﬁed12 and
many of them are fatal, therefore, this class of IEMs will be an
important future extension of the human metabolic reconstruc-
tion. In contrast, the inclusion of the non-metabolic IEM will
require the expansion of the metabolic reconstruction for
further cellular processes, such as signalling,73–75 macromolecular
synthesis,76–78 and transcriptional regulation.76,79,80
The presented extension to the current human metabolic recon-
struction is not only important and relevant to map and analyze
newborn screening data but also to map large-scale metabolomic
data sets of plasma and urine from deﬁned patient groups. For
instance, serum metabolite concentration data for more than
1000 participants have been recently published, along with their
genetic variants, from the KORA population.81 Thanks to our
extension, a majority of these metabolite measurements could be
mapped and analyzed within the metabolic network context.
Table 1 Properties of mapped IEMs explained using classical phenylketonuria (PKU, OMIM: 261600) as an example
Criteria Deﬁnition Characterization of PKU
Pathway classiﬁcation IEMs were classiﬁed according to their metabolic
pathways
Amino acid metabolism
Aﬀected genes Mutations in the gene lead to (i) non-functional
protein, (ii) mutated protein, or (iii) no protein
synthesis. All these instances give rise to an IEM
Phenylalanine hydroxylase (PAH, GeneID: 5053, E.C.
1.14.16.1)
Aﬀected reactions Genes encode enzymes that catalyze reactions. IEMs
are seen due to enzyme deﬁciencies, transporter, or
co-factor defects; thereby, reactions are either
blocked or follow abnormal pathways
O2 + phenylalanine + tetrahydrobiopterin > tyrosine +
dihydrobiopterin + H2O (PHETHPTOX2 in Recon 1).
Accumulated phenylalanine produces phenylacetate and
phenyllactate as abnormal metabolites
Mode of inheritance IEMs are inherited in a dominant or recessive
pattern. Majority of the IEMs are autosomal
recessive
Phenylketonuria follows an autosomal recessive pattern of
inheritance
Phenotypes A single metabolic defect may present various
phenotypic patterns, which may range from two to
seven diﬀerent forms (see text and ESI)
Three major types: phenylketonuria (PKU), non-PKU
hyperphenylalaninemia and variant PKU
Aﬀected organs The severity of the IEMs is assessed by their ability to
aﬀect organ systems. While some of the IEMs may be
un-noticed, many of them have profound eﬀects on
diﬀerent organ systems
Brain
Biomarkers Biomarkers enable easy and early diagnosis of IEMs In plasma: increased phenylalanine and phenylalanine/tyrosine
ratio. In urine: increased excretion of 2-hydroxyphenylacetic
acid, phenyl lactic acid, and phenyl pyruvic acid
Therapies available IEMs, when diagnosed at a young age, are
often treatable. Various therapeutic measures
are available, including dietary interventions,
medications, gene therapy, enzyme replacement,
and organ transplantation
Phenylalanine restricted diet. In fact, most disorders of
amino acid metabolism are controlled by dietary interventions
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Metabolism has been found to be abnormal in many
diseases. In this study, we identiﬁed potential IEM hubs in
the metabolic network, which are connected by inter-linking
metabolites. The use of comprehensive mathematical meta-
bolic models for the analysis of IEMs is promising, especially,
for those IEMs, which have currently no diagnosis. Moreover,
computational modelling may be particularly valuable for
those IEMs that are very rare and have currently no promising
diagnostic and therapeutic regime.
Materials and methods
Routinely measured biomarkers in newborn screening data
We used information obtained from the Landspı´tali (Icelandic
National University Hospital) for routinely measured biomarkers,
which include 18 standard and four non-standard amino acids
(i.e., argininosuccinate, methylhistidine, ornithine and citrulline),
36 acylcarnitines, and 23 ratios (of amino acids and acylcarnitines)
(see Table S1 (ESIz) for a complete list). Furthermore, we
considered three additional acylcarnitines (C14:1-OH, C16:2-OH,
C14:2-OH) to be mapped onto the human reconstruction.
Note that measured methylhistidine concentrations cannot
be mapped onto the human reconstruction. We retrieved the
molecular formulae and chemical structure for each meta-
bolite from the literature and/or databases.
Human metabolic reconstruction
The published human metabolic reconstruction, Recon 1,16
was obtained from the BiGG database82 in SBML format83
and loaded into our reconstruction tool, rBioNet,84 using
the COBRA toolbox.85 Recon 1 consists of 3743 reactions,
2766 metabolites, and 1905 transcripts (corresponding to
1495 unique genes). Genes are connected to their respective
reactions based on Boolean logic by deﬁning gene–protein-
reaction (GPR) associations for each network reaction. AND
signiﬁes that two gene products are required to carry out one
reaction (enzyme complex), while OR stands for either gene
product is suﬃcient for the reaction (isozyme).
AC/FAO reconstruction module
The reconstruction was done using an established protocol14
and the rBioNet reconstruction extension84 for the COBRA
toolbox.85 Besides information retrieved from more than 150
primary publications and books, we used numerous databases
(Table S7, ESIz). Reaction directionality information was
obtained from the literature and/or from thermodynamic
considerations.86–88 We employed the COBRA toolbox to
combine the AC/FAO module with Recon 1, and named the
resulting expanded reconstruction Recon1_AC/FAO. The
content of the AC/FAO module can be found in Table S9,
ESI.z
IEM collection and analysis
Candidate IEMs were mapped onto Recon1_AC/FAO using
GPR associations in Recon1_AC/FAO and reported aﬀected
gene(s) of an IEM. Phenotypic and clinical information for
each IEM was retrieved from primary literature, books, and
databases (Table S8, ESIz). A complete list of mapped andTa
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future IEMs along with their characteristics can be found in
Tables S2 and S3 (ESIz), respectively.
Network based analysis of IEMs
Using the GPR associations deﬁned in Recon1_AC/FAO, we
mapped all 235 IEMs onto the network. The reconstruction
was converted into a mathematical model using the COBRA
toolbox. The resulting stoichiometric matrix, S, has m rows,
one for each metabolite, and n columns, one for each reaction.
If a metabolite i participates in a reaction j, then the cell S(i,j)
has a non-zero entry, where the number corresponds to the
stoichiometric coeﬃcient of the corresponding reaction j. By
deﬁnition, substrates have a negative coeﬃcient, while pro-
ducts have a positive coeﬃcient. Similarly, the model of
Recon1_AC/FAO contains a matrix describing the links
between genes and reactions, deemed G. Using G, we mapped
the IEMs from genes to reactions, resulting in a new matrixM,
in which each row corresponds to an IEM and each column
corresponds to a reaction. Using a binary version ofM (Mbin),
we multiplied Mbin with its transpose. Each diagonal element
of this adjacency matrix ofMbin corresponds to the number of
reactions that are connected with each IEM. The oﬀ-diagonal
elements corresponding to the number of reactions shared
between two IEMs, which allowed us to identify reaction
pairs. Similarly, by multiplying the Mbin with the transpose
of the binary version of S, Sbin, we could determine meta-
bolites shared between two IEMs. For the visualization of all
IEMs, we employed the pathway viewer from the KEGG
database.89
Simulation of PKU
Recon1_AC/FAO was converted into a computational model
using the COBRA toolbox.85 The reaction list of the recon-
struction was therefore converted into a so-called stoichio-
metric matrix, S, consisting of m rows (one row for each
metabolite) and n columns (one for each reaction in the
network). If a metabolite i participates in a reaction j, then
the entry Si,j contains the corresponding non-zero stoichio-
metric coeﬃcient, which is a negative number for substrates
and a positive number for reaction products. Constraint-based
modelling assumes that the modelled system is in a quasi-
steady state, i.e., the change of concentration of a metabolite i
is zero over time t: di/dt = Sv  0 where v is the ﬂux vector
containing a ﬂux value vi for each reaction i. In ﬂux balance
analysis, we generally optimize for an objective reaction, thus
identifying one possible ﬂux vector with optimal value in
the objective function that is consistent with the applied
constraints.71,90 Constraints can be applied to any reaction i in
the model, such that vi,minr vir vi,max. To simulate PKU, we set
the constraints of the reaction PHETHPTOX2, catalyzed byPAH,
to vPHETHPTOX2,min = vPHETHPTOX2,max = 0 mmol gDW
1 h1,
while the constraints through this reaction in the healthy model
were unchanged. Additionally, for the healthy and PKU models,
we set the lower bounds (vi,min) of the exchange reactions for water,
carbon dioxide, proton, bicarbonate, ammonium, inorganic
phosphate and sulphate to100 mmol gDW1 h1, and the lower
bound for oxygen uptake was set to be 40 mmol gDW1 h1.
The lower bounds of the remaining exchange reactions were
set to be 1 mmol gDW1 h1. The upper bounds of all exchange
reactions were unconstrained, i.e., vi,max= 1000 mmol gDW
1 h1.
In both models, we selected the exchange reaction for L-tyrosine
and L-phenylalanine separately as objective reactions for
maximisation and minimisation. The calculations were carried
out using Matlab (Mathworks, Inc.) as programming environ-
ment and TomLab (TomOpt, Inc.) as linear programming
solver.
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